Jonathan Polak

Jonathan Polak has a diverse work experience, spanning from 2002 to the present. Jonathan is currently the Chief Executive Officer at Mesentech, where they focus on developing drugs for patients with advanced osteoporosis and brittle bone disease. Prior to this, from 2016 to 2018, they worked as the Head of Business Development at Novateur Ventures Inc., where they brought healthcare and life science companies to market. From 2012 to 2016, they founded and led Datapoint Diagnostics, a company that pioneered digital phenotyping as a clinical tool in neurology. Before that, they served as the Vice President of Business Development at Intelescope Solutions Ltd., an Israeli AgriTech company specialized in Brazil silviculture. Jonathan also has experience as a Hedge Fund Trader at Fulcrum Capital, an Associate in Special Projects at Perimeter Markets (a portfolio company of the Goldman Sachs Group), a Management Consultant at Deutsche Post International, and in International Business Development at Onewave Technologies. Additionally, they worked as a Market Research Analyst at IBM and as a Summer Research Intern at Teknillinen korkeakoulu-Tekniska högskolan.

Jonathan Polak attended the University of Toronto from an unknown start year to 2007, where they obtained a Bachelor of Engineering degree in Electrical and Computer Engineering. In the same year, they also attended the University of Toronto - Rotman School of Management, although the specific degree obtained is not stated. Prior to their time at the University of Toronto, Jonathan attended CHAT from 1996 to 2000. No specific degree or field of study is mentioned for this institution.